Kronos Bio, Inc.

Healthcare · Biotechnology · United States

Last price 0.88 USD (At close: Jun 20, 2025) · Market cap 53.73M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren’s disease. The company was incorporated in 2017 and is headquartered in San M...